Brainstorm Cell TherapeuticsSTU:GHD 28 EV-to-FCF is -2.30 as of Jul. 08, 2026. GuruFocus rates STU:GHD with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 327 Biotechnology companies, Brainstorm Cell Therapeutics ranks worse than 305810.09% on this metric.
The historical rank and industry rank for Brainstorm Cell Therapeutics's EV-to-FCF or its related term are showing as below:
STU:GHD'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.37 Med: 0 Max: 0
Current: -2.37
STU:GHD's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs STU:GHD: -2.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Brainstorm Cell Therapeutics's PE Ratio (TTM) for today is calculated as:
Brainstorm Cell Therapeutics's share price for today is €2.979.
Brainstorm Cell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.792.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Brainstorm Cell Therapeutics EV-to-FCF Related Terms
Brainstorm Cell Therapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:GHD vs ADAPY, APRE, JSPR: EV-to-FCF Comparison
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brainstorm Cell Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's EV-to-FCF falls into.
Brainstorm Cell Therapeutics's current Enterprise Value is €13.24 Mil.
Brainstorm Cell Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics (STU:GHD) has a EV-to-FCF of -2.30 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Brainstorm Cell Therapeutics and its competitors. According to the industry distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry.
Is Brainstorm Cell Therapeutics' EV-to-FCF too high?
Brainstorm Cell Therapeutics' current EV-to-FCF is -2.30. Based on the distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' EV-to-FCF compare to ADAPY and APRE?
According to the Biotechnology industry distribution chart, Brainstorm Cell Therapeutics ranks #999999 out of 327 companies for EV-to-FCF. This places Brainstorm Cell Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Brainstorm Cell Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brainstorm Cell Therapeutics's current EV-to-FCF is -2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current EV-to-FCF of -2.30. The current EV-to-FCF is -2.30. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current EV-to-FCF is -2.30 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score
Get the complete analysis for STU:GHD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:GHD has been successfully added to your 
